Evidence map›Paper›PMID 40407985›Full record

ArticleDiscover oncology2025

Long non-coding RNA TMEM51-AS1 inhibits colorectal cancer progression.

Dongping Wu, Qing Xia, Xinming Su, Yunan Mao, Jiwei Mao, Qiannan Ding, Jianjiang Liu, Wangyan Zhong, Xiaoyu Zhang, Hanbing Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dongping Wu *Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Qing Xia *College of Pharmacy, Zhejiang University of Technology, Hangzhou, 310014, Zhejiang, China.
Xinming SuKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, 310014, Zhejiang, China.
Yunan MaoKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, 310014, Zhejiang, China.
Jiwei MaoDepartment of Radiation Oncology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Qiannan DingMedical Research Center, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Jianjiang LiuDepartment of Radiation Oncology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Wangyan ZhongDepartment of Radiation Oncology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Xiaoyu ZhangDepartment of Radiation Oncology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Hanbing LiCollege of Pharmacy, Zhejiang University of Technology, Hangzhou, 310014, Zhejiang, China. hanbing.li@163.com.
Shiwei DuanKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, 310014, Zhejiang, China. duansw@hzcu.edu.cn.

Funding

Clinical Research Foundation of Zhejiang Province Medical Association 2020ZYC-B17
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most common cause of death worldwide and has high mortality and a poor prognosis. Long non-coding RNAs (lncRNAs) are non-coding RNAs longer than 200 nucleotides that play roles in cancer through multiple mechanisms. TMEM51-AS1 is a newly discovered 40,650 bp lncRNA. Our results showed that TMEM51-AS1 expression was significantly downregulated in CRC tissues (fold change = 0.74, P < 0.0001). This finding was confirmed in 20 pairs of CRC carcinoma and paracancerous tissues (fold change = 0.5, P < 0.001). Additionally, TMEM51-AS1 expression was found to be significantly reduced in CRC cell lines compared to normal human intestinal epithelial cells (P < 0.001). Bioinformatic analysis revealed that TMEM51-AS1 expression was associated with immune escape, RNA methylation, and DNA damage and repair. TMEM51-AS1 may also activate energy metabolism pathways to participate in cancer development. Drug sensitivity analysis confirmed that several drugs are more effective in CRC patients with high expression of TMEM51-AS1. In conclusion, our study demonstrates that TMEM51-AS1 can suppress the progression of CRC.

Indexed as

CRCDownregulationExpressionLncRNAProgressionTMEM51-AS1

Identifiers

PMID40407985
PMCPMC12102048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.